PMID- 34938657
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211224
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Overexpression of B7-H3 Is Associated With Poor Prognosis in Laryngeal Cancer.
PG  - 759528
LID - 10.3389/fonc.2021.759528 [doi]
LID - 759528
AB  - The immune checkpoint molecule, B7-H3, which belongs to the B7 family, has been 
      shown to be overexpressed in various cancers. Its role in tumors is not well 
      defined, and many studies suggest that it is associated with poor clinical 
      outcomes. The effect of B7-H3 on laryngeal cancer has not been reported. This 
      study investigated the expression of B7-H3 in laryngeal squamous cell carcinoma 
      (LSCC), and its relationship with clinicopathological factors and prognosis of 
      LSCC patients. The gene expression quantification data and clinical data of LSCC 
      retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) 
      database were analyzed to determine the diagnostic and prognostic roles of B7-H3. 
      Quantitative real-time polymerase chain reaction (qRT-PCR) was then performed to 
      determine the gene expression level of B7-H3 between LSCC tissues and paired 
      normal adjacent tissues. In addition, TCGA RNA-seq data was analyzed to evaluate 
      the expression level of B7 family genes. Next, the protein expression of B7-H3 
      and CD8 in LSCC was determined using immunohistochemistry and immunofluorescence. 
      qRT-PCR results showed that the expression level of B7-H3 mRNA was significantly 
      higher in LSCC tissues than in adjacent normal tissues. Similar results were 
      obtained from the TCGA analysis. The expression of B7-H3 was significantly 
      associated with T stage, lymph node metastasis, and pathological tumor node 
      metastasis (TNM) stage, and it was also an independent factor influencing the 
      overall survival time (OS) of patients with LSCC. In addition, B7-H3 was 
      negatively correlated with CD8(+)T cells. These results show that B7-H3 is 
      upregulated in LSCC. Therefore, B7-H3 may serve as a biomarker of poor prognosis 
      and a promising therapeutic target in LSCC.
CI  - Copyright (c) 2021 Li, Cai, Shen, Chen and Guan.
FAU - Li, Yixuan
AU  - Li Y
AD  - Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Cai, Qian
AU  - Cai Q
AD  - Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Shen, Ximing
AU  - Shen X
AD  - Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Chen, Xiaoting
AU  - Chen X
AD  - Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Guan, Zhong
AU  - Guan Z
AD  - Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20211206
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8685272
OTO - NOTNLM
OT  - B7-H3
OT  - LSCC - laryngeal squamous cell carcinoma
OT  - biomarker
OT  - diagnosis
OT  - prognosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/12/24 06:00
MHDA- 2021/12/24 06:01
PMCR- 2021/01/01
CRDT- 2021/12/23 05:52
PHST- 2021/08/16 00:00 [received]
PHST- 2021/10/12 00:00 [accepted]
PHST- 2021/12/23 05:52 [entrez]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2021/12/24 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.759528 [doi]
PST - epublish
SO  - Front Oncol. 2021 Dec 6;11:759528. doi: 10.3389/fonc.2021.759528. eCollection 
      2021.